CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens

Bone Marrow Transplantation

Volumn 19, Issue 11, 1997, Pages 1095-1101

  Holyoake, T L ^a   Alcorn, M J ^a   Richmond, L ^a   Farrell, E ^a   Pearson, C ^a   Green, R ^b   Dunlop, D J ^a   Fitzsimons, E ^c   Pragnell, I B ^d   Franklin, I M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b W of Scotland Blood Transfus Serv   (United Kingdom)

^c MONKLANDS HOSPITAL   (United Kingdom)

^d BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

CD34 positive; Ex vivo expansion; Myeloablative chemoradiotherapy; PBPC

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CELL CULTURE; COLONY FORMING UNIT GM; CONDITIONING; CONTROLLED STUDY; HUMAN; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE; TREATMENT FAILURE; WHOLE BODY RADIATION;

EID: 0030920565     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700799     Document Type: Article

References (17)

1. + cells into the myeloid lineage. Blood 1992; 80: 1405-1412.
2. + progenitor cells by stem cell factor, interleukin-1β (IL-1β), IL-6, IL-3, interferon-γ and erythropoietin. Blood 1993; 81: 2579-2584.
3. +-selected human peripheral blood progenitor cells. Blood 1994; 84: 2898-2903.
4. + cells from patients with stage IV breast cancer. Blood 1994; 84: 3567-3574.
5. Brugger W, Heimfeld S, Berenson RJ et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. New Engl J Med 1995; 333: 283-287.
6. Alcorn MJ, Holyoake TL, Richmond L et al. CD34-positive cells isolated from cryopreserved peripheral blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996; 14: 1839-1847.
7. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
8. + hematopoietic progenitor cells: implications for the expansion of contaminating tumor cells. Exp Hematol 1995; 23 (Suppl. 1): 845 (Abstr. 357).
9. + peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Blood 1996; 88: 2707-2713.
10. + cells: feasibility and safety associated with clinical use. Blood 1995; 86 (Suppl. 1): 294a (Abstr. 1164).
11. Champlin R, Mehra R, Gajewski L et al. Ex vivo expanded progenitor cell transplantation in patients with breast cancer. Blood 1995; 86 (Suppl. 1): 295a (Abstr. 1166).
12. + cells by flow cytometry: application to the harvesting and transplantation of peripheral blood stem cells. In: Wunder E, Sovalat H, Hénon Ph, Serke S (eds). Hematopoietic Stem Cells: The Mulhouse Manual. AlphaMed Press: Dayton, OH, 1994, pp 31-43.
13. Holyoake TL, Alcorn MJ. CD34 positive hematopoietic cells: biology and clinical applications. Blood Rev 1994; 8: 113-124.
14. Gribben J, Linch DC, Singer CRJ et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
15. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843 and 895-902.
16. + hematopoietic progenitors. In: Gee AP, Gross S, Worthington-White DA (eds). Advances in Bone Marrow Purging and Processing. Fourth International Symposium. Wiley-Liss: New York, 1994, pp 217-228.
17. Sutherland HJ, Hogge DE, Lansdorp PM et al. Quantitation, mobilization, and clinical use of long-term culture-initiating cells in blood cell autografts. J Hematother 1995; 4: 3-10.